Syros to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on August 5, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and provide a corporate update. Interested parties can join the call by dialing 866-595-4538 domestically or 636-812-6496 internationally, using conference ID 4156527. The call can also be accessed via the Syros website, with a replay available for 30 days post-event. Syros is focused on developing innovative gene expression control therapies for cancer and other serious diseases.
- Syros is advancing a robust clinical-stage pipeline, including tamibarotene for myelodysplastic syndrome and acute myeloid leukemia.
- SY-2101, an oral form of arsenic trioxide, is in development for acute promyelocytic leukemia.
- SY-5609, a selective oral CDK7 inhibitor, targets certain solid tumors.
- None.
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 5, 2021 to report its second quarter 2021 financial results and provide a corporate update.
To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 4156527. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005069/en/
FAQ
When will Syros Pharmaceuticals report its second quarter 2021 financial results?
What is the conference call ID for the Syros Pharmaceuticals Q2 2021 earnings call?
How can I access the Syros Pharmaceuticals Q2 2021 earnings call?
What are the main products in Syros Pharmaceuticals' clinical pipeline?
